Anti-inflammatory agent, the composition containing this tool, the method of treatment of skin and systemic inflammatory diseases

 

(57) Abstract:

The invention relates to medicine and refers to the extract from plants of the family Labiatae, cultured in in vitro conditions, in the form of a cosmetic or pharmaceutical composition comprising as active ingredient an effective amount of the above-mentioned extract, which is intended for the treatment of cutaneous or systemic inflammatory diseases, with more favorable results. 3 C. and 16 h.p. f-crystals, 1 table.

The invention, in its broadest aspect, relates to an extract of at least one plant of the family Labiatae, cultivated in vitro.

It also relates to cosmetic or pharmaceutical compositions containing as active ingredient at least an effective amount of the extract, the use in a cosmetic composition or for preparing a pharmaceutical composition as an active ingredient for the treatment of diseases which are accompanied by inflammatory or allergic process, an effective amount of at least of this extract and a method of cosmetic treatment using this extract.

In the following text, the expression "the Labiatae extract" is (or inflammation) is a complex biological reactions, which occurs throughout the animal Kingdom. In humans, two of the three diseases, accompanied by inflammatory syndrome. Inflammation may be localized. It can be defined as the first response to any local aggression by a number of nonspecific reactions that are triggered regardless of the original cause and occur in three phases: vascular, cellular and vascular tissue fibrosis.

Swelling, pain, redness, fever are terms that can be used to describe local inflammation. In General, these signs result from infiltration of the tissues damaged as a result of edema and/or expansion of the capillaries.

Symptoms of inflammation include fever, General discomfort and/or increase the concentration of some proteins of blood plasma.

This phenomenon, which includes, inter alia, a number of local cellular responses and the release of cytokines and other mediators such as substance P, prostaglandins, leukotriene, bradykinin, histamine or serotonin.

It also manifests itself in the change of blood flow at the level of the damaged areas, increase vascular permeability, which in turn leads to the release of blood plasma proteins and CL is palenia.

In fact, these phenomena are the result of the action of inflammatory mediators.

Among the factors involved in the development of inflammatory reaction, may be mentioned cytokines, especially including interleukin-1 , interleukin-1 , interleukin-6, tumor necrotic factors (TNF - a and chemokines, such as interleukin-8 or monotany chemotactic and activating factor (MCAF) or other chemotactic factors responsible for the increase in the number of lymphocytes, monocytes, Langerhans cells and basophils in the site of inflammation, such as In-4 leukotriene or other factors involved in the cascade development of inflammatory reactions, such as arachidonic acid, prostaglandins, especially including prostaglandin E2.

Inflammation is associated with numerous pathological conditions. As an example, mention can be made of rheumatic diseases. Such as acute articular rheumatism, rheumatoid arthritis, pulmonary diseases such as emphysema, joint diseases such as arthritis, tendonitis, periarthritis, spondyloarthropathy, joint disorders in chronic enteropathy, allergies, inflammatory stage of alopecia, skin diseases, such as sensitive skin, erythema, is h, insect bites and other dermatological diseases such as atrophic polyhedric, erythemally, necrobiosis lipoidica or diffuse erythematous lupus.

In allergic conditions have been also involved cytokines, especially interleukin-1 and interleukin-1 and tumor necrotic factors-type (TNF ).

In contrast to inflammatory reactions allergic reaction is a condition in which the responsible external factor or an allergen. In this case, this specific immunological process that takes place only if there is an allergen, and which affects only sensitised subjects.

However, ultimately, allergic reaction also leads to acute inflammation together with swelling.

Whatever was a phenomenon, there is shared between all of these mechanisms that lead to inflammatory reactions, the ultimate manifestation of which can be assessed by exudation, fat skin cells and at least one of the mediators of inflammation, such as histamine, serotonin, heparin, leukotrien, prostaglandine, cytokines, monoxide nitrogen or reactive saturated with oxygen connection.

For Alenia or allergies. In this regard, there are many substances which have already been described, and they are known in the literature under the names of steroid or non-steroidal anti-inflammatory drugs (SAID or NSAID), a description of which can be found, for example, in the book Schorderet and Dayer "Pharmacologie, Des conceprs fondamentaux aux applications therapeutiques", 1992, Chapter 37, pages 541-561, 2nd edition ed. Frison - Roeche/Slatkine.

Aside from the fact that many anti-inflammatory medications often have significant side effects, it remains important to have new products with anti-inflammatory activity.

The present invention is to create a new product with anti-inflammatory and antiallergic activity does not have a significant adverse effect.

This objective and others are achieved by the present invention, the object of which is to extract at least one plant of the family Labiatae, characterized in that said plant is cultivated in vitro.

Anti-inflammatory effect of the extract of plants of the family Labiatae known per se. In this regard, mention can be made of patent application FR-A-2504551, JP-A-7017846, WO-A - 9325209, SU-A-1733000, FR-A-26662078, DE-A-3536342, US 5393526.

However, it is surprising and unexpected is the first anti-inflammatory activity compared with the activity, show the extract of the whole plants grown in vivo. Moreover, the text will present the results of experiments on binding to receptors of inflammatory mediators, which have been established these facts.

The object of the invention, therefore, is an extract of at least one plant of the family Labiatae, in vitro.

Selection of physico-chemical conditions of the growth of plant cells in vitro makes it possible to obtain a standardized plant material available throughout the year in contrast to plants, cultivated in vivo.

Under cultivation in vitro should understand a number of techniques known to the skilled in this field personnel. That gives the possibility to artificially obtain plants or parts of plants.

Plant material used according to the invention, can be any plant material, obtained by cultivation in vitro. Thus, this means that it can be the whole plant or specific authority. Specifically, the plant material can be plant cells, and more specifically, undifferentiated (or nedifferencirovannaja) of plant cells.

Under adifferent spetsificheskoi standardization and able to exist by themselves and independently of other cells. Perhaps these undifferentiated plant cells are able, in the induction, to any type of differentiation according to their genome.

Depending on the chosen method of cultivation and especially depending on the selected culture medium, it is possible to obtain from the same Explant undifferentiated plant cells with different properties.

In the family Labiatae is about 2700 species.

Thus, the extract according to the invention can be prepared from plant material Labiatae plants, selected from genus Lavandula, Mentha, Preslia, Lycopus, Origanum, Thymus, Hyssopus, Satureia, Micromeria, Calamentha, Melissa, Horminium, Rosmarinus, Salvia, Nereta, Dracocephalum, Glechoma, Lamium, Leonurus, Galeopsis, Stachys, Betonica, Ballota, Phlomis, Sideritis, Marrubium, Melittis, Scutelloria, Brunella, Ajuga and Teucrium.

Preferably, if the extract according to the invention can be prepared from plant material Labiatae plants, selected from genus Lavandula, Mentha, Preslia, Origanum, Thymus, Melissa, Rosmarinus and Salvia, more preferably from the genus Rosmarinus.

The extract according to the invention can be prepared from plant material obtained from selected species of Lavandula spica. Origanum vulgare, Thymus vulgaris, Melissa officinalis, or Rosmarinus officinalis.

More specifically the invention Extensa least one Labiatae plants can be extract, made from plant material obtained from the family Labiatae, cultured in vitro.

Any extraction method known to the skilled in this field personnel can be used for the preparation of an extract according to the invention.

Especially may be mentioned alcohol, especially ethanol or aqueous-alcoholic extracts.

It is also possible to use the extract prepared according to the method described in the French patent application N 95-02379 included by the applicant.

Thus, initially, the plant material is crushed in water at low temperature, in the second stage removes the particles from the aqueous solution obtained in the first stage, and in the third stage, the aqueous solution obtained in the second stage, sterilized. Aqueous solution and is the extract.

Then the extract may be dried by sublimation.

The first stage can be with advantage replaced by a simple operation of the freezing of plant tissues (for example, at -20oC) followed by extraction with water as described above for the second and third stages.

If the plant material is a whole plant, fresh conditions as for the material obtained in vitro. Various plant parts are removed, respectively, the relative mass of each part.

Processing at low temperature makes it possible to inactivate the enzymes freezing, sterilizing filtration to avoid decomposition of active compounds under the action of microorganisms in the environment. Finally, the aquatic environment is comparable with receptors ex vivo and suitable for cosmetic and pharmaceutical forms.

It is known that plant extracts contain oxidase, responsible, inter alia, for the oxidation of the above extracts. In this case, this oxidation leads to the dark brown colour of the extracts and the emergence of a pungent smell. Which makes them unsuitable for use in cosmetics. In this regard, particularly known laccase (n-diphenyloxides) with a molecular weight of more than 100000 daltons.

Thus, it is useful if the resulting extract can be fractionated using any known method of fractionation, which allows you to remove oxidase and especially polyphenoloxidase. The extract of the invention can, for example, be filtered on a membrane for dialysis to remove molecules with a molecular the LASS="ptx2">

You can use other methods for protection against oxidation. More specifically, the extract can stabilize. You can use any known method of stabilization according to the invention. For example, it is possible to stabilize the extract of the invention by addition of a cysteine to a final concentration of between 0.5 g/l and 10 g/l and preferably between 1.5 g/l and 2.5 g/l

Obviously the extract according to the invention it is possible to fractionate and stabilize.

Presents the example, moreover, examples of the preparation of the extract, which can be used according to the invention.

The object of the invention is also a cosmetic or pharmaceutical composition comprising, in a suitable cosmetic and pharmaceutical environment, as active ingredient, at least one extract of at least one Labiatae plants, as defined above.

More specifically, the pharmaceutical composition is a dermatological composition.

The amount of extract that is included in the composition according to the invention, of course, depends on the desired effect and, therefore, varies widely.

When determining order quantities, should proceed from the fact that the EU is 50% by weight of the total composition and preferably in amounts of 0.005% to 25% by weight of the total composition.

When determining order quantities should proceed from the fact that if the composition is a pharmaceutical, it can contain the extract defined above, in amounts of from 0.01% to 70% by weight of the total composition and preferably in amounts of from 0.05% to 40% by weight of the total composition.

Examples of diseases, which accompanies the inflammatory process, have been given above in the text.

These inflammatory disorders can be cutaneous or systemic.

Thus, the composition according to the invention is intended for the treatment of skin and systemic diseases in which there is inflammation.

More specifically, the composition according to the invention is suitable for the treatment of rheumatic diseases, such as acute articular rheumatism, rheumatoid arthritis, pulmonary diseases such as emphysema, diseases of the joints such as osteoarthritis, tendent, periarthritis, spondyloarthropathy, or joint damage in chronic enteropathy, allergies, inflammatory phases in alopecia, skin diseases, such as sensitive skin, erythema, particularly as a result of UV-irradiation, itching, erythema nodosum, urticaria, systemic mastocytosis, psoriasis, insect bites, and other dermatologist is up scattered erythematous lupus.

Another preferred if the composition of the invention are used to treat skin irritation and/or Stripping, and/or loss of sensitivity (dysesthesia), and/or sensitivity when overheating, and/or itching of the skin and/or mucous membranes.

The composition according to the invention can be administered orally, injection, or skin (any skin area of the body), hair, nails and mucous membranes (cheeks, cheeks, gums, genitals and conjunctivitis). Depending on the route of administration of the composition according to the invention can be any of the commonly used medical forms.

Specifically for external use on the skin, the composition may be in the form of aqueous or oil solution or a dispersed system type of lotion or serum, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O/W) or conversely (W/O), or suspensions or emulsions of soft consistency of the type of aqueous or anhydrous cream or gel or microcapsules or microparticles, or of vesicular dispersions of ionic and/or nonionic type. These compositions are prepared by conventional methods.

They can also be applied to the hair in an aqueous, alcoholic or aqueous/alcoholic rallet under pressure.

For injection route of administration of the composition can be used in the form of aqueous or oily lotion or in the form of a serum. To the eye it can be used in the form of drops, and for oral administration in the form of capsules, granules, syrups or tablets.

The number of different components of the compositions according to the invention are the same as commonly used in the preparation of the reviewed forms.

More specifically, these compositions are cleansing, protective, treatment creams, care creams for the face, Rog, legs, large anatomical folds or for the body (for example day creams, night creams, creams for removing make-up, creams under powder, creams against sunburn), fluid under powder, lotion, makeup remover, protective lotion or lotion body care. Jelly against tanning lotions for skin care, gels or foams, such as lotions for cleansing, against the sun, artificial tanning lotions, compositions for the bath, deodorants, including a bactericidal substance, gels or lotions after shaving, depilatory creams, compositions used for insect bites, composition against pain or compositions for treating certain skin diseases such as eczema, red acne, psoriasis, l is non Soaps or pills.

Also the composition can be included in the aerosol form comprising a propellant under pressure.

Also, the composition according to the invention can be a composition for hair care, in particular a shampoo, a lotion to soak the hair before styling lotion for care cream or gel for styling hair, paint (particularly for bleaching hair). In particular, in the form of coloring shampoos, lotion for hair straightening, the composition for perming type "permanent" (especially compositions for the first stage waving "permanent"), liquids or gels anti hair loss, anti-parasitic shampoos and the like.

Also the composition can be applied to the teeth and oral cavity, for example, in the form of toothpaste. In this case, the composition may contain conventional adjuvants and additives used in the preparation of compositions for the oral cavity and, in particular, surfactants, thickeners, humectants, polishing agents such as silica, various active ingredients such as fluorides, especially sodium fluoride, and possibly sweeteners such as sodium saccharinate.

If the composition is an emulsion, the fat content the total weight of the composition. Using the composition in the form of an emulsion choose oils, waxes, emulsifiers and simulatory commonly used in the field of cosmetology. Emulsifiers and simulatory present in the composition in an amount of from 0.3% to 30% by weight and preferably from 0.5% to 20% by weight relative to the total weight of the composition. In addition, the emulsion can include lipid vesicles.

If the composition is an oily gel or solution, the fatty phase may represent more than 90% of the total weight of the composition.

When using the known methods, the composition can also include adjuvants commonly used in cosmetics, such as hydrophilic or lipophilic gel agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, fragrances, fillers, masking agents, odor absorbers and colorants. The quantities of these various adjuvants are the same as usually used in the field of cosmetology, and, for example, they comprise from 0.01% to 10% by weight of the total composition. These adjuvants, depending on the nature, can be introduced into the fatty phase or the aqueous phase and/or into the lipid balls.

Because the invention can use the La Chi, sunflower oil), oils of animal origin (perhydrosqualene), synthetic oils (oil Purcellin), silicone oils or waxes (cyclomethicone) and fluorinated oils (parfocality), beeswax, Carnauba and paraffin waxes. These oils can be added to the fatty alcohols and fatty acids (stearic acid).

As examples of emulsifiers that can be used in the invention, mention can be made of glycerol stearate, Polysorbate 60 and the mixture of Page-6/ Page-32/glycol stearate, with the trade name Tefose63, the production company Gattefosse.

As solvents that can be used in the invention, mention can be made of lower alcohols, especially ethanol and isopropanol, propylene glycol.

As hydrophilic gelling agents which can be used in the invention, mention can be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and lipophilic gelling agents, mention can be made of modified clays such as bentonites, metal salts of fatty acids, t is I can include other hydrophilic active compounds, such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and derivatives of sugars, water-soluble vitamins, plant extracts and hydroxy acid.

As lipophilic active agents can be used retinol (vitamin a) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils, salicylic acid and its derivatives.

According to the invention the composition may include at least one extract from one Labiatae plants together with other active substances for the prevention and/or treatment of skin diseases. Among these active substances as an example we can mention:

substances that alter the differentiation and/or proliferation and/or pigmentation of the skin, such as retinova acid and its isomers, retinol and its esters, vitamin D and its derivatives, oestrogens such as oestradiol, kojic acid, hydroquinone;

antibacterial agents such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline;

antiparasitic drugs, especially metronidazole, crotamiton or pyrethroids;

antifungal drugs, especially coee connection such as amphotericin b, the substance of a number of allylamines, such as terbinafine or octopirox;

antiviral drugs such as acyclovir;

steroid anti-inflammatory drugs, such as hydrocortisone, betamethasone valeriat or clobetasol propionate, or nonsteroidal anti-inflammatory drugs such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid, acetaminophen or glycyrrhetinic acid;

anesthetics, such as lidocaine hydrochloride and its derivatives;

drugs to combat the itching, such as analgin, trimeprazine or cyproheptadine;

keratolytic agents, such as, or hydroxycarboxylic acids or ketocarboxylic acids, their salts, amides or esters and especially hydroxy acid such as glycolic acid, lactic acid, salicylic acid, citric acid and, in General, fruit acids and 5-n-actinomycetoma acid;

drugs acting against free radicals, such as-tocopherol and its esters, dismutation peroxide, some metal chelates and ascorbic acid and its esters;

antisubmarine drugs such as progesterone;

preparations for dandruff, such as octopirox or zinc Piri is their plants and/or microorganisms.

Thus, for the specific purpose of the invention relates to compositions containing at least one extract of at least one Labiatae plants and at least one drug selected from a range of antibacterial, antiparasitic, antifungal, antiviral, anti-inflammatory drugs, against itching, anaesthetic, keratolytic compounds, substances acting against free radicals, antiseborrheic drugs, dandruff and acne, compounds modulating the differentiation and/or proliferation and/or pigmentation of the skin, extracts of other plants and/or microorganisms.

The object of the invention is also the use as an active ingredient in a cosmetic composition or for the preparation of pharmaceutical compositions, an effective amount of at least one extract, above, for the treatment of diseases, which accompanies the inflammatory process, as described above.

Mainly according to the invention at least one extract of at least one Labiatae plants can be joined with products with irritating, which is usually used in production is somaticheskih and pharmaceutical compositions. The presence of the extract of at least one Labiatae plants in cosmetic or pharmaceutical compositions comprising the product with the irritant, can significantly reduce or completely remove this irritant effect.

In addition, this makes it possible to increase the amount of active ingredient to improve the efficiency compared to the normally used amount of the active ingredient.

More specifically the invention relates to cosmetic or pharmaceutical compositions containing at least one product with irritating and at least one extract of at least one Labiatae plants acceptable for cosmetic and pharmaceutical environment.

As an example, products with irritating and without limitation, the assumption may be mentioned surfactants (ionic or nonionic), preservatives, organic solvents or active drugs, such as hydroxy acid (citric, malic, glycolic, tartaric, almond or lactic acid)- hydroxy acid (salicylic acid and its derivatives), a keto acid, a keto acid, retinoids (retinol, Minoxidil, lithium salts, antimetabolites, vitamin D and its derivatives, paints and painting tools for hair (para-phenylenediamine and its derivatives, aminophenols), flavouring alcoholic solutions (perfume, toilet water, aftershave, deodorants), anti-sweating (some aluminium salts), active preparations for hair removal or active means for Curling hair type is "permanent" (thiols), depigmenting active agents (hydroquinone).

More specifically the invention relates to cosmetic or pharmaceutical compositions containing at least one extract of at least one Labiatae plants and at least one product with the irritant selected from such active compounds, such as hydroxy acid (citric, malic, glycolic, tartaric, almond or lactic acid)- hydroxy acid (salicylic acid and its derivatives), a keto acid, a keto acid, retinoids (retinol, retinal, retinova acid), anthralin (dioxiranes), anthranoid, peroxides (especially benzoyl peroxide), Minoxidil, lithium salts, antimetabolites, vitamin D and its derivatives, paints and painting tools for hair (para-phenylenediamine and its derivatives, aminophenols), money is ivci hair type is "permanent" (thiols), depigmenting active agents (hydroquinone) acceptable for cosmetic and pharmaceutical environment.

The use of at least one extract of at least one Labiatae plants especially makes it possible to increase from 2 to 10 times the amount of the active ingredient with irritating compared to normal in the absence of the aforementioned uncomfortable actions. Thus, it is possible to use hydroxy acid to 50% by weight of the composition or retinoids to 5%, significantly compromising their irritant effect.

In addition, an object of the present invention is a method of cosmetic treatment in order to reduce the irritating cosmetic composition, comprising applying to the skin, hair and/or mucous membranes of the composition, as described above.

Method of cosmetic treatment according to the invention can be performed, in particular, when using hygienic or cosmetic compositions as defined above, conventional methods of using these compositions. For example, the application of creams, gels, sera, lotions, milk makeup remover or compositions against tan skin or dry hair, apply the moose is ture and composition without any restrictions illustrate the invention. In the compositions of the above quantities are expressed in percent by mass.

Example 1: preparation of extract of undifferentiated cells Rosmarinus officinalis cultivated in vitro:

Undifferentiated cells Rosmarinus officinalis, cultured in axenically conditions, is removed by filtration under nitrogen through a 50 μm filter after cultivation in Erlenmeyer flasks or fermenter. 1 ml of deionized water containing 1.8 g/l cysteine, added to 1 g of the thus obtained with fresh material. All ground (Potter, Ultra Turrax) at Turrax at 24000 rpm/min for 1 minute at 4oC (ice bath). The crushed product is centrifuged for 15 minutes at 10000 g at 4oC. the Supernatant passed through a 0.22 μm filter (sterilizuya filtering).

Thus prepared, the extract stored at 4oC. It contains about 15 g of dry material per liter.

Then extract fractionary by ultrafiltration on a membrane type Sartorius, in order exemption oxidase.

Thus, the resulting aqueous extract, which can be used directly (aqueous extract).

The extract was dried by sublimation (dried by sublimation of the Torno affinity extracts of Rosmarinus officinalis in relation to B2, IL-1 , IL-6, TNF and HI receptors:

Determination of receptor affinity of the extract of Rosmarinus officinalis in relation to the B2 receptor was carried out according to the method described in the article: Burch, R. M. et al., Biotech update (DuPont NEN), 7: 3-11; (1992).

Determination of receptor affinity of the extract of Rosmarinus officinalis in relation to IL-1 receptor was carried out according to the method described in the article: Bird T. A. et al., FEBS Letter, 225: 21-26; (1987).

Determination of receptor affinity of the extract of Rosmarinus officinalis against IL-6 receptor was carried out according to the method described in the article: T. Taga Et al., J. Exp. Med., 166: 967-981; (1987).

Determination of receptor affinity of the extract of Rosmarinus officinalis in relation to the TNF receptor was carried out according to the method described in the article: Brockhaus, M. et al., P. N. A. S., 87: 3127-3131; (1990).

Determination of receptor affinity of the extract of Rosmarinus officinalis in relation to HI receptors was carried out according to the method described in the article: Dini S. et al., Agents and Actions, 33: 181-184 (1991).

Extracts, prepared as described in example 1 was tested in a concentration of 0.5%, 2% and 5%.

For every experience, standard molecules for studying receptor (NPC 567 for B2 receptor, IL-1 to IL-1 receptor, IL-6 to IL-6 receptor, TNF to TNF receptor and pyrilamine for HI receptor) were tested in parallel in 8 the end is 2">

The results of these experiments are presented in the table: data are expressed as percent inhibition of the binding relative to the control.

The results of these experiments showed the presence of the affinity of the extract of Rosmarinus officinalis in relation to the receptors of inflammatory mediators. Specifically, extracts of undifferentiated cells have high affinity to multiple receptors of inflammatory mediators.

Stable and/or filtered extracts thus prepared for the inhibition and/or removal of certain enzymes, especially oxidase, retain an affinity for the receptors of inflammatory mediators.

These extracts are good anti-inflammatory drugs wide steps.

Example 3: examples of forms illustrating the invention and especially the composition of the invention comprising at least one extract of Rosmarinus officinalis and the product with the irritant.

These compositions were obtained by simple mixing of the individual components.

Composition 1: lotion makeup remover with the entity, %:

The extract from example 1 (aqueous form) - 10,00

Antioxidant - 0,05

Isopropanol - 40,00

Preservative - 0,30

Water - To 100cel H, sold by Hercules) - 1,00

Flavouring substance - 0,50

Preservative - 0,30

Water Up to 100

Composition 3: a care cream for the face (emulsion oil-in-water), %:

The extract from example 1 (dried by sublimation of form) - 0,20

Stearate glycerin - 2,00

Polysorbate 60 (tween 60 sold by the company ICI) - 1,00

Stearic acid - 1,40

Triethanolamine - 0,70

Carbomer - 0,40

Lipid fraction of Shea butter - 12,00

Perhydroxyl - 12,00

Antioxidant - 0,05

Flavouring substance - 0,50

Preservative - 0,30

Water Up to 100

Track 4: the gel for the treatment of acne, %:

The extract from example 1 (dried by sublimation of form) - 0,50

TRANS-retinova acid - 0,05

Hydroxypropylcellulose (Klucel H sold by Hercules) - 1,00

Antioxidant - 0,05

Isopropanol - 40,00

Preservative - 0,30

Water Up to 100

Composition 5: gel for skin care entity, %:

The extract from example 1 (aqueous form) - 5,00

Hydroxypropylcellulose (Klucel H sold by Hercules) - 1,00

Antioxidant - 0,05

Isopropanol - 40,00

Preservative - 0,30

Water Up to 100

Track 6: anesthetic gel, %:

The extract from example 1 (aqueous form) - 10,00

the chloride - 2,00

Isopropanol - 40,00

Preservative - 0,30

Water Up to 100

Track 7: the cream for use in solar erythema (emulsion oil-in-water), %:

The extract from example 1 (dried by sublimation of form) - 0,50

Stearate glycerin - 2,00

Polysorbate 60 (tween 60 sold by the company ICI) - 1,00

Stearic acid - 1,40

Glycyrrhetinic acid - 2,00

Triethanolamine - 0,70

Carbomer - 0,40

Lipid fraction of Shea butter - 12,00

Sunflower oil - 10,00

Antioxidant - 0,05

Flavouring substance - 0,50

Preservative - 0,30

Water Up to 100

Song 8: the cream from wrinkles for the face (oil/water emulsion), %:

The extract from example 1 (aqueous form) - 5,00

Stearate glycerin - 2,00

Polysorbate 60 (tween 60 sold by the company ICI) - 1,00

Stearic acid - 1,40

5-n-actinomycetoma acid - 0,50

Triethanolamine - 0,70

Carbomer - 0,40

Lipid fraction of Shea butter - 12,00

Perhydroxyl - 12,00

Antioxidant - 0,05

Flavouring substance - 0,50

Preservative - 0,30

Water Up to 100

Composition 9: lotion for removing scars resulting from acne, %:

The extract from example 1 (aqueous form) - 5,00

Glycolic KIS is Up to a pH of 2.8

Ethanol Up To 100.

1. The use of the extract of plants of the family Labiatae, cultured in vitro, as anti-inflammatory agents.

2. Application under item 1, characterized in that the plant is Labiatae genus selected from Lavandula, Mentha, Preslia, Lycopus, Origanum, Thymus, Hyssopus, Satureia, Micromeria, Calamentha, Melissa, Horminium, Rosmarinus, Salvia, Nepeta, Dracocephalum, Glechoma, Lamium, Leonurus, Galeopsis, Stachys, Betonica, Ballota, Phlomis, Sideritis, Marrubium, Melittis, Scutellaria, Brunella, Ajua and Teucrium.

3. Use PP.1 and 2, characterized in that the Labiatae plant is from a genus selected from Lavandula, Mentha, Preslia, Origanum, Thymus, Melissa, Rosmarinus and Salvia.

4. Use PP.1 to 3, characterized in that the Labiatae plant is of the genus Rosmarinus.

5. Use PP.1 to 4, characterized in that the plant is Rosmarinus officinalis.

6. Use PP.1 to 5, characterized in that the tool represents an extract of plant cells.

7. Use PP.1 - 6, characterized in that the plant cells are undifferentiated cells.

8. Use PP.1 to 7, characterized in that the extract is fractionated to remove oxidase.

9. Use PP.1 to 8, characterized in that the extract is stable.

11. Use PP. 1 to 9, characterized in that the pharmaceutical composition of the extract containing 0.01 - 70%, preferably 0.05 to 40% by weight of the total composition.

12. Use PP.1 - 11 for the treatment of skin and systemic inflammatory diseases.

13. Use PP.1 - 12 for the treatment of rheumatic diseases, lung diseases, joint diseases, allergies, inflammatory phase of alopecia, skin disorders, insect bites.

14. Use PP.1 - 13 for the treatment of skin irritations and/or Stripping, and/or loss of sensitivity (dysesthesia), and/or sensitivity when Parinirvana, and/or itching of the skin and/or mucous membranes.

15. Use PP.1 - 14, wherein the extract further comprises the product with the irritant.

16. Cosmetic or pharmaceutical composition having anti-inflammatory activity, characterized in that it contains extract of plants of the family Labiatae on PP.1 - 11 and the product with the irritant in an effective amount in an acceptable environment.

17. The composition according to p. 16, characterized in that the product with the irritant is selected from surface-and the as-hydroxy acid (citric, malic, glycolic, tartaric, almond or lactic acid)- hydroxy acid (salicylic acid and its derivatives), a keto acid, a keto acid, retinoids(retinol, retinal, retinova acid), anthralin (dioxiranes), anthranoid, peroxides (especially benzoyl peroxide), Minoxidil, lithium salts, antimetabolites, vitamin D and its derivatives, paints and painting tools for hair (para-phenylenediamine and its derivatives, aminophenols), flavouring alcoholic solutions (perfume, toilet water, aftershave, deodorants), anti-sweating (some aluminium salts), active preparations for hair removal or active means for Curling hair type is "permanent" (thiols), depigmenting active agents (hydroquinone).

18. The composition according to p. 17, characterized in that the product with the irritant is selected from the active compounds, such as hydroxy acid (citric, malic, glycolic, tartaric, almond or lactic acid)- hydroxy acid (salicylic acid and its derivatives), a keto acid, a keto acid, retinoids (retinol, retinal, retinova acid), anthralin (dioxiranes), anthranoid, peroxides (especially benzoyl peroxide), Minoxidil, lithium salts, antimet the derivative, aminophenols), anti-sweating (some aluminium salts), active preparations for hair removal or active means for Curling hair type is "permanent" (thiols), depigmenting active agents (hydroquinone).

19. The method of treatment of skin and systemic inflammatory diseases, characterized in that the cosmetic composition according to PP.1 - 10 or 12 - 18 applied to the skin, hair and/or mucous membranes in an effective amount.

 

Same patents:

The invention relates to new triaromatic compounds of General formula I, characterized in p

The invention relates to medicine, namely to rheumatology, and can be used for treatment of juvenile rheumatoid arthritis predominantly articular form

The invention relates to veterinary medicine, in particular to methods for prevention of acute respiratory disease of calves, and can be used for prevention of the respiratory system, mainly acute respiratory infections of bacterial etiology

The invention relates to medicine, in particular to pulmonology, and can be used for the treatment of erosive or ulcerative tracheobronchitis

The invention relates to medicine, more specifically to anesthesiology and critical care medicine, and may find application in the prevention and treatment of critical conditions in the case of direct lung gastric contents

The invention relates to medicine, more specifically to anesthesiology and critical care medicine, and may find use for the treatment of respiratory insufficiency II-III severity

The invention relates to medicine, more specifically to anesthesiology and critical care medicine, and may find application in the treatment of respiratory failure nicardipine of nature in critical States

The invention relates to medicine, namely to resuscitation, and may find application in neonatology

The invention relates to medicine, namely to pulmonology, and may find application in the treatment of acute pneumonia in children in the presence of atelectasis as a complication of pneumonia

The invention relates to substituted azetidinone General formula I listed in the description

The invention relates to the field of medicine and for the application of polymer alkylarylsulfonates for effective inhibition of oxidant in chemical or biological system, as well as medications, including those polymeric compounds
The invention relates to the field of dermatology and can be used in the construction industry, in industry and everyday life
The invention relates to the field of dermatology and can be used in the construction industry, in industry and everyday life

The invention relates to the field of cosmetics

The invention relates to the field of cosmetics

The invention relates to the field of cosmetics
Hair gel // 2150267
The invention relates to cosmetic and for the production of tools for hair care
After shave cream // 2150266
The invention relates to cosmetic and can be used in the manufacture of cosmetic products after shave

The invention relates to cosmetic compositions for washing and conditioning hair
Up!